Investor Contact
For investor related questions, please email
investors@aclaristx.com

Press Releases

Press Releases

December 5, 2023
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
November 13, 2023
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
November 6, 2023
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
October 3, 2023
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
September 20, 2023
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 18, 2023
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
August 7, 2023
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
June 13, 2023
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
June 2, 2023
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
May 8, 2023
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 2, 2023
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
March 27, 2023
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 6, 2023
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
February 23, 2023
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
February 9, 2023
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
January 6, 2023
Aclaris Therapeutics Provides 2023 Outlook
Load More »